Attached files

file filename
EX-99.1 - EX-99.1 - Aptose Biosciences Inc.d102569dex991.htm
EX-5.1 - EX-5.1 - Aptose Biosciences Inc.d102569dex51.htm
EX-1.1 - EX-1.1 - Aptose Biosciences Inc.d102569dex11.htm





Washington, D.C. 20549








July 15, 2020

(Date of Report – date of earliest event reported)



Aptose Biosciences Inc.

(Exact Name of Registrant as Specified in Its Charter)




Canada   001-32001   98-1136802

(State or Other Jurisdiction of

Incorporation or Organization)

  (Commission File Number)  

(I.R.S. Employer

Identification No.)

251 Consumers Road, Suite 1105 Toronto, Ontario M2J 4R3



M2J 4R3

(Address of Principal Executive Offices)     (Zip Code)

(647) 479-9828

(Registrant’s Telephone Number, Including Area Code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class


Trading Symbol(s)


Name of each exchange on which registered

Common Shares, no par value    APTO    The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒




Item 1.01. Entry into a Material Definitive Agreement.

On July 15, 2020, Aptose Biosciences Inc. (“Aptose”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Piper Sandler & Co., as representative of the underwriters identified therein (collectively, the “Underwriters”), pursuant to which Aptose agreed to issue and sell 10,500,000 common shares at a public offering price of $5.25 per common share (the “Offering”). Under the terms of the Underwriting Agreement, Aptose granted the Underwriters a 30-day option to purchase up to an additional 1,575,000 common shares. Aptose expects to receive approximately $51.6 million in net proceeds from the Offering (excluding the option to purchase additional shares), after deducting underwriting discounts and commissions but before deducting estimated offering expenses. The common shares are being offered and sold pursuant to the Company’s effective registration statement on Form S-3 (Registration No. 333-235730) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission (the “SEC”) on January 9, 2020, and the base prospectus included therein, as amended and supplemented by the preliminary prospectus supplement filed with the SEC on July 15, 2020, and the final prospectus supplement which will be filed with the SEC. The Offering is expected to close on or about July 20, 2020, subject to satisfaction of customary closing conditions.

The above description of the Underwriting Agreement is qualified in its entirety by the Underwriting Agreement, which is attached to this report as Exhibit 1.1 and which is incorporated by reference into the Registration Statement.

Item 7.01. Regulation FD Disclosure.

On July 15, 2020, Aptose issued a press release announcing that it had priced the Offering, which press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

In connection with the Offering, Aptose is filing a legal opinion and consent as Exhibit 5.1 and Exhibit 23.1 to this report, which are incorporated by reference into the Registration Statement.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


Exhibit 1.1    Underwriting Agreement, dated July 15, 2020, between Aptose Biosciences Inc. and Piper Sandler & Co.
Exhibit 5.1    Opinion of McCarthy Tetrault LLP
Exhibit 23.1    Consent of McCarthy Tetrault LLP (included in Exhibit 5.1)
Exhibit 99.1    Press Release, dated July 15, 2020


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:    July 16, 2020





/s/ Gregory K. Chow



Gregory K. Chow


  Senior Vice President & Chief Financial Officer